SCHEMBL27010384

SCHEMBL27010384

CC(C)C1(F)CCN(Cc2ccc(S(=O)(=O)N3CCOCC3)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
TSHR P16473 3/20 0.54
POLB P06746 1/20 0.46
LMNA P02545 3/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
CYP2D6 P10635 3/20 0.44
MEN1 O00255 2/20 0.44
MAPK1 P28482 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.43
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27010251 0.94 TSHR (0.60) ALDH1A1TSHRPOLBLMNAGAA
SCHEMBL27010254 0.94 ALDH1A1 (0.54) ALDH1A1TSHRPOLBLMNAGAA
SCHEMBL27010317 0.92 ALDH1A1 (0.60) ALDH1A1TSHRPOLBLMNAGAA
SCHEMBL27010377 0.87 L3MBTL1 (0.47) ALDH1A1TSHRPOLBLMNASMN1; SMN2
SCHEMBL24317829 0.85 ALDH1A1 (0.57) ALDH1A1TSHRPOLBLMNAGAA
SCHEMBL26620374 0.85 TSHR (0.57) ALDH1A1TSHRPOLBLMNAGAA
SCHEMBL24315675 0.85 ALDH1A1 (0.54) ALDH1A1TSHRPOLBLMNAGAA
SCHEMBL27010252 0.83 TSHR (0.60) ALDH1A1TSHRPOLBLMNAGAA
SCHEMBL26620051 0.82 TSHR (0.63) ALDH1A1TSHRPOLBLMNAGAA
SCHEMBL26620378 0.82 TSHR (0.60) ALDH1A1TSHRPOLBLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 ALDH1A1 2267/4885TSHR 2445/4885POLB 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.